[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-001", "question": "A 16-year-old male presents with recurrent stroke-like episodes, mitochondrial myopathy, and lactic acidosis. Muscle biopsy reveals 38% heteroplasmy for the m.3243A>G mutation. Based on current mitochondrial disease criteria, what is the significance of this heteroplasmy level?", "options": ["Insufficient for MELAS diagnosis; >60% required in muscle", "Diagnostic of MELAS; clinical correlation unnecessary", "Above the threshold for clinical expression; supports diagnosis with compatible phenotype", "Only significant if confirmed in blood at >20%", "Requires repeat biopsy; sampling error likely"], "answer": "C", "answer_index": 2, "explanation": "In MELAS, >40% heteroplasmy in muscle correlates with clinical manifestation, but levels of 30-40% with typical phenotype are considered diagnostic. Blood heteroplasmy is less sensitive and declines with age. The threshold concept is critical for interpreting borderline results.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is logically valid and medically sound for a board-style exam. The vignette describes a classic presentation of MELAS (stroke-like episodes, myopathy, lactic acidosis). The core task is to interpret the significance of finding the m.3243A>G mutation at 38% heteroplasmy in muscle. While the biochemical threshold for cellular dysfunction in individual fibers is often cited as high (60–90%), the detection of the pathogenic mutation at 38% in a symptomatic patient is diagnostic and confirms the molecular etiology. Option C is the best answer because it correctly links the positive biopsy finding with the clinical phenotype to support the diagnosis. Option A is incorrect; there is no absolute cutoff of >60% required for diagnosis if the phenotype and mutation are present. Option B is incorrect because genetic testing requires clinical correlation. Option D is incorrect because blood heteroplasmy decreases with age and is less sensitive than muscle. Option E is incorrect because the finding is positive and consistent with the disease, not an error. The item functions well as a 'best answer' question.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is logically valid and medically sound for a board-style exam. The vignette describes a classic presentation of MELAS (stroke-like episodes, myopathy, lactic acidosis). The core task is to interpret the significance of finding the m.3243A>G mutation at 38% heteroplasmy in muscle. While the biochemical threshold for cellular dysfunction in individual fibers is often cited as high (60–90%), the detection of the pathogenic mutation at 38% in a symptomatic patient is diagnostic and confirms the molecular etiology. Option C is the best answer because it correctly links the positive biopsy finding with the clinical phenotype to support the diagnosis. Option A is incorrect; there is no absolute cutoff of >60% required for diagnosis if the phenotype and mutation are present. Option B is incorrect because genetic testing requires clinical correlation. Option D is incorrect because blood heteroplasmy decreases with age and is less sensitive than muscle. Option E is incorrect because the finding is positive and consistent with the disease, not an error. The item functions well as a 'best answer' question.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-002", "question": "A 19-year-old asymptomatic athlete has a QTc of 315ms on pre-participation screening. Family history reveals sudden cardiac death in a paternal uncle. Genetic testing identifies a gain-of-function KCNH2 mutation (c.1764G>C). According to 2022 ESC guidelines for SQTS, what is the recommended management?", "options": ["No therapy; restriction from competitive sports", "Implantable cardioverter-defibrillator regardless of symptoms", "Quinidine 600mg daily to maintain QTc >360ms", "Flecainide 100mg twice daily for rhythm stabilization", "Annual Holter monitoring without pharmacotherapy"], "answer": "C", "answer_index": 2, "explanation": "For asymptomatic SQTS patients with pathogenic KCNH2 mutations, quinidine is recommended to prolong QT interval and reduce arrhythmia risk. ICD is reserved for symptomatic patients or those with aborted SCD. Flecainide is contraindicated in SQTS.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with Short QT Syndrome (SQTS) type 1, indicated by the QTc of 315 ms and the gain-of-function KCNH2 mutation. The family history of sudden cardiac death (SCD) places the patient in a higher risk category despite being asymptomatic. According to the 2022 ESC Guidelines for Ventricular Arrhythmias and the Prevention of SCD, an ICD (Option B) is not indicated for asymptomatic patients (Class III). Quinidine (Option C) is the specific pharmacological therapy of choice for SQTS (particularly KCNH2 variants) and is listed as a Class IIb recommendation ('may be considered') for asymptomatic patients with a family history of SCD. While 'No therapy' (Option A) is a defensible approach given the weak (IIb) recommendation, the presence of a malignant family history and the availability of a genotype-specific therapy (Quinidine) make Option C the 'best' answer in a board-exam context. Option A includes sports restriction (which is correct) but fails to address the risk of non-exertional arrhythmia, which is common in SQTS. Therefore, C is the unique best answer among the choices.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with Short QT Syndrome (SQTS) type 1, indicated by the QTc of 315 ms and the gain-of-function KCNH2 mutation. The family history of sudden cardiac death (SCD) places the patient in a higher risk category despite being asymptomatic. According to the 2022 ESC Guidelines for Ventricular Arrhythmias and the Prevention of SCD, an ICD (Option B) is not indicated for asymptomatic patients (Class III). Quinidine (Option C) is the specific pharmacological therapy of choice for SQTS (particularly KCNH2 variants) and is listed as a Class IIb recommendation ('may be considered') for asymptomatic patients with a family history of SCD. While 'No therapy' (Option A) is a defensible approach given the weak (IIb) recommendation, the presence of a malignant family history and the availability of a genotype-specific therapy (Quinidine) make Option C the 'best' answer in a board-exam context. Option A includes sports restriction (which is correct) but fails to address the risk of non-exertional arrhythmia, which is common in SQTS. Therefore, C is the unique best answer among the choices.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-003", "question": "A 62-year-old woman with Graves disease presents in thyroid storm (Burch-Wartofsky score 65) with pulmonary edema and cardiogenic shock (LVEF 15%, CI 1.8 L/min/m²). She cannot tolerate beta-blockers due to severe decompensation. Which vasoactive agent is most appropriate initial therapy?", "options": ["Norepinephrine for vasopressor support", "Dobutamine for inotropic effect", "Milrinone 0.5 mcg/kg/min for inodilation", "Levosimendan 0.1 mcg/kg/min calcium sensitizer", "Dopamine 10 mcg/kg/min for combined effect"], "answer": "C", "answer_index": 2, "explanation": "In thyroid storm with cardiogenic shock, beta-blockers are contraindicated. Milrinone provides inotropy via phosphodiesterase inhibition independent of beta-adrenergic receptors and offers vasodilation to reduce afterload. Levosimendan is less preferred due to limited data and potential arrhythmogenicity.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question describes a patient with thyroid storm complicated by severe cardiogenic shock (CI 1.8) and pulmonary edema (LVEF 15%). The key clinical constraints are the hyperadrenergic state of thyroid storm and the inability to tolerate beta-blockers. \\n\\n1.  **Pathophysiology:** In thyroid storm, beta-adrenergic receptors are upregulated or overstimulated. Adding beta-adrenergic agonists (Dobutamine, Dopamine) can exacerbate the storm, arrhythmias, or be ineffective due to receptor downregulation/uncoupling.\\n2.  **Hemodynamics:** The patient has pulmonary edema and low output. Pure vasoconstrictors (Norepinephrine) increase afterload, potentially worsening LVEF and pulmonary edema unless contractility is addressed. \\n3.  **Mechanism:** Milrinone (PDE3 inhibitor) provides inotropy and afterload reduction (inodilation) independent of the beta-adrenergic receptor, making it the ideal physiologic choice for thyrotoxic heart failure. \\n4.  **Distractors:** Levosimendan is a valid alternative but is often considered a distractor in US-centric exams due to availability; Norepinephrine is standard for undifferentiated shock but suboptimal as monotherapy for this specific hemodynamic profile (high afterload sensitivity). \\n\\nWhile the stem omits blood pressure (a critical factor for initiating milrinone safely), the combination of 'thyroid storm' and 'pulmonary edema' strongly points to non-adrenergic inodilation as the intended teaching point.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question describes a patient with thyroid storm complicated by severe cardiogenic shock (CI 1.8) and pulmonary edema (LVEF 15%). The key clinical constraints are the hyperadrenergic state of thyroid storm and the inability to tolerate beta-blockers. \n\n1.  **Pathophysiology:** In thyroid storm, beta-adrenergic receptors are upregulated or overstimulated. Adding beta-adrenergic agonists (Dobutamine, Dopamine) can exacerbate the storm, arrhythmias, or be ineffective due to receptor downregulation/uncoupling.\n2.  **Hemodynamics:** The patient has pulmonary edema and low output. Pure vasoconstrictors (Norepinephrine) increase afterload, potentially worsening LVEF and pulmonary edema unless contractility is addressed. \n3.  **Mechanism:** Milrinone (PDE3 inhibitor) provides inotropy and afterload reduction (inodilation) independent of the beta-adrenergic receptor, making it the ideal physiologic choice for thyrotoxic heart failure. \n4.  **Distractors:** Levosimendan is a valid alternative but is often considered a distractor in US-centric exams due to availability; Norepinephrine is standard for undifferentiated shock but suboptimal as monotherapy for this specific hemodynamic profile (high afterload sensitivity). \n\nWhile the stem omits blood pressure (a critical factor for initiating milrinone safely), the combination of 'thyroid storm' and 'pulmonary edema' strongly points to non-adrenergic inodilation as the intended teaching point.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-004", "question": "A 6-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. ADA2 enzyme activity is <5% of normal. Genetic testing confirms biallelic loss-of-function ADA2 mutations. What is the first-line therapy for preventing further cerebrovascular events?", "options": ["High-dose prednisone with cyclophosphamide induction", "Rituximab 750mg/m² every 4 weeks", "Etanercept 0.8mg/kg weekly subcutaneously", "Anakinra 2mg/kg daily subcutaneously", "Aspirin 5mg/kg daily antiplatelet therapy"], "answer": "C", "answer_index": 2, "explanation": "DADA2 is a monogenic interferonopathy where TNF-α drives vasculitic manifestations. TNF inhibition with etanercept prevents stroke recurrence and treats systemic vasculitis, while traditional immunosuppressants are ineffective. IL-1 blockade is second-line.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a classic presentation of Deficiency of Adenosine Deaminase 2 (DADA2), confirmed by genetics and enzyme activity. The primary clinical concern in DADA2 is recurrent ischemic strokes caused by vasculitis. Medical consensus and literature (e.g., NEJM 2014, Meyts et al.) establish TNF inhibitors (specifically etanercept) as the first-line treatment of choice to prevent stroke recurrence and control vasculitis in DADA2. Traditional immunosuppressants like cyclophosphamide and steroids (Option A) are the standard for Polyarteritis Nodosa (PAN) but have been shown to be largely ineffective for stroke prevention in DADA2. Antiplatelet agents (Option E) do not address the underlying inflammation and may increase hemorrhagic risk. IL-1 blockade (Option D) is not the standard first-line therapy compared to TNF inhibition. Therefore, Option C is the unique best answer. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a classic presentation of Deficiency of Adenosine Deaminase 2 (DADA2), confirmed by genetics and enzyme activity. The primary clinical concern in DADA2 is recurrent ischemic strokes caused by vasculitis. Medical consensus and literature (e.g., NEJM 2014, Meyts et al.) establish TNF inhibitors (specifically etanercept) as the first-line treatment of choice to prevent stroke recurrence and control vasculitis in DADA2. Traditional immunosuppressants like cyclophosphamide and steroids (Option A) are the standard for Polyarteritis Nodosa (PAN) but have been shown to be largely ineffective for stroke prevention in DADA2. Antiplatelet agents (Option E) do not address the underlying inflammation and may increase hemorrhagic risk. IL-1 blockade (Option D) is not the standard first-line therapy compared to TNF inhibition. Therefore, Option C is the unique best answer. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-005", "question": "A 30-year-old G2P1 at 32 weeks gestation presents with fetal hydrops and mirror syndrome. Which pathophysiologic mechanism best explains her severe preeclampsia-like features?", "options": ["Massive fetomaternal hemorrhage causing maternal anemia", "Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)", "Maternal antibody production against fetal Rh antigens", "Amniotic fluid embolism triggering systemic inflammation", "Mirror syndrome is a misdiagnosis; this is atypical HELLP"], "answer": "B", "answer_index": 1, "explanation": "Mirror syndrome involves placental edema that mechanically compromises uteroplacental perfusion and releases anti-angiogenic factors like sFlt-1, creating a preeclampsia phenotype. Resolution occurs within 48 hours of delivery or fetal therapy that reduces hydrops.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item describes a classic case of Mirror syndrome (Ballantyne syndrome), defined by the triad of fetal hydrops, placental edema, and maternal preeclampsia-like symptoms. The question specifically asks for the pathophysiologic mechanism driving the maternal features. Current obstetric literature supports that the edematous placenta releases anti-angiogenic factors, particularly soluble fms-like tyrosine kinase-1 (sFlt-1), which causes maternal endothelial dysfunction similar to preeclampsia. Option B correctly identifies this mechanism. Options A (fetomaternal hemorrhage) and C (Rh alloimmunization) are potential etiologies for the fetal hydrops itself, but they do not directly explain the mechanism of the maternal systemic response (the 'mirroring'). Option D describes an acute embolic event, which is clinically distinct. Option E is incorrect because Mirror syndrome is a recognized entity distinct from HELLP, though they share features. The item is medically accurate, logically sound, and the key is supported by current evidence.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item describes a classic case of Mirror syndrome (Ballantyne syndrome), defined by the triad of fetal hydrops, placental edema, and maternal preeclampsia-like symptoms. The question specifically asks for the pathophysiologic mechanism driving the maternal features. Current obstetric literature supports that the edematous placenta releases anti-angiogenic factors, particularly soluble fms-like tyrosine kinase-1 (sFlt-1), which causes maternal endothelial dysfunction similar to preeclampsia. Option B correctly identifies this mechanism. Options A (fetomaternal hemorrhage) and C (Rh alloimmunization) are potential etiologies for the fetal hydrops itself, but they do not directly explain the mechanism of the maternal systemic response (the 'mirroring'). Option D describes an acute embolic event, which is clinically distinct. Option E is incorrect because Mirror syndrome is a recognized entity distinct from HELLP, though they share features. The item is medically accurate, logically sound, and the key is supported by current evidence.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-006", "question": "A 50-year-old with eosinophilic granulomatosis with polyangiitis undergoes cardiac MRI for suspected myocarditis. Late gadolinium enhancement shows predominant subendocardial involvement with sparing of the epicardium. What is the prognostic implication?", "options": ["Indicates active eosinophilic myocarditis responsive to steroids", "Suggests concomitant coronary artery disease requiring angiography", "Represents fibrotic replacement predicting poor response to immunosuppression", "Typical pattern with no impact on treatment decisions", "Requires endomyocardial biopsy for definitive diagnosis"], "answer": "C", "answer_index": 2, "explanation": "In EGPA, subendocardial LGE pattern indicates chronic fibrotic replacement rather than active inflammation, predicting poor response to immunosuppressive therapy and worse cardiac outcomes. Epicardial LGE correlates with active myocarditis and treatment responsiveness.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is underspecified and relies on flawed medical logic. In Eosinophilic Granulomatosis with Polyangiitis (EGPA), cardiac involvement typically progresses from an acute necrotic stage to a thrombotic/fibrotic stage (Loeffler’s endocarditis). Both the acute necrotic stage (active inflammation) and the chronic fibrotic stage manifest as subendocardial late gadolinium enhancement (LGE). Therefore, the LGE pattern described cannot definitively distinguish between active disease responsive to steroids (Option A) and chronic fibrosis (Option C) without additional information such as T2-weighted imaging (for edema) or clinical chronicity. The author’s rationale—that epicardial LGE correlates with active myocarditis in EGPA—contradicts established pathology; active eosinophilic myocarditis is characteristically subendocardial or transmural, whereas epicardial involvement is typical of viral/lymphocytic myocarditis. Additionally, Option B (CAD) is a strong distractor, as subendocardial LGE is the hallmark of ischemia, which is a plausible differential in a 50-year-old. To make Option C the unique best answer, the stem must specify the absence of edema or a chronic clinical course.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is underspecified and relies on flawed medical logic. In Eosinophilic Granulomatosis with Polyangiitis (EGPA), cardiac involvement typically progresses from an acute necrotic stage to a thrombotic/fibrotic stage (Loeffler’s endocarditis). Both the acute necrotic stage (active inflammation) and the chronic fibrotic stage manifest as subendocardial late gadolinium enhancement (LGE). Therefore, the LGE pattern described cannot definitively distinguish between active disease responsive to steroids (Option A) and chronic fibrosis (Option C) without additional information such as T2-weighted imaging (for edema) or clinical chronicity. The author’s rationale—that epicardial LGE correlates with active myocarditis in EGPA—contradicts established pathology; active eosinophilic myocarditis is characteristically subendocardial or transmural, whereas epicardial involvement is typical of viral/lymphocytic myocarditis. Additionally, Option B (CAD) is a strong distractor, as subendocardial LGE is the hallmark of ischemia, which is a plausible differential in a 50-year-old. To make Option C the unique best answer, the stem must specify the absence of edema or a chronic clinical course.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-007", "question": "An 11-month-old infant presents with a large CNS tumor. Histopathology shows rhabdoid cells with loss of SMARCB1 immunostaining. Molecular profiling reveals a TYR-methylation class. What is the most critical prognostic factor in this subtype?", "options": ["Presence of SMARCB1 deletion alone", "Age <3 years at diagnosis", "MYC oncogene amplification status", "DNA methylation subclassification", "Extent of surgical resection"], "answer": "D", "answer_index": 3, "explanation": "In ATRT, the methylation class (TYR, SHH, MYC) is the dominant prognostic factor, with TYR class having 90% 5-year survival compared to <30% for MYC. SMARCB1 loss is universal, and age is secondary to molecular subclassification in risk stratification.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: Miskeyed (K). \\nVerdict: The item is logically flawed because the question stem restricts the patient population to a specific subgroup ('TYR-methylation class'), yet the keyed answer ('DNA methylation subclassification') is the factor defining that subgroup. A defining constant cannot serve as a prognostic variable *within* the group it defines (tautology). \\n\\nLogical Issue: The question asks for a prognostic factor 'in this subtype.' Since the patient is already defined as TYR, their methylation class is fixed. The only option representing a variable prognostic factor applicable *within* the TYR subtype is Option E (Extent of surgical resection), which is a well-established predictor of outcome in ATRT. Option D would be the correct answer if the question asked, 'What is the most critical prognostic factor for *ATRT patients in general*?' or 'What factor best explains this patient's specific prognosis?'. \\n\\nMedical Accuracy: The rationale cites a 90% 5-year survival for TYR-ATRT, which is optimistic compared to major studies (e.g., Torchia et al., *Lancet Oncol* 2016, reporting ~37-70% depending on the cohort), though it is correctly identified as the favorable subtype compared to MYC. \\n\\nFix: Rewrite the question to: 'Which factor is the strongest predictor of overall survival in patients with this diagnosis (ATRT)?' to validate Option D.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: Miskeyed (K). \nVerdict: The item is logically flawed because the question stem restricts the patient population to a specific subgroup ('TYR-methylation class'), yet the keyed answer ('DNA methylation subclassification') is the factor defining that subgroup. A defining constant cannot serve as a prognostic variable *within* the group it defines (tautology). \n\nLogical Issue: The question asks for a prognostic factor 'in this subtype.' Since the patient is already defined as TYR, their methylation class is fixed. The only option representing a variable prognostic factor applicable *within* the TYR subtype is Option E (Extent of surgical resection), which is a well-established predictor of outcome in ATRT. Option D would be the correct answer if the question asked, 'What is the most critical prognostic factor for *ATRT patients in general*?' or 'What factor best explains this patient's specific prognosis?'. \n\nMedical Accuracy: The rationale cites a 90% 5-year survival for TYR-ATRT, which is optimistic compared to major studies (e.g., Torchia et al., *Lancet Oncol* 2016, reporting ~37-70% depending on the cohort), though it is correctly identified as the favorable subtype compared to MYC. \n\nFix: Rewrite the question to: 'Which factor is the strongest predictor of overall survival in patients with this diagnosis (ATRT)?' to validate Option D.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-008", "question": "A 76-year-old man with wild-type transthyretin amyloidosis (ATTRwt) has LV wall thickness 16mm and LVEF 45%. Which speckle-tracking echocardiographic finding best distinguishes this from hypertensive heart disease?", "options": ["Global longitudinal strain -8%", "Relative apical sparing ratio >1.5", "Basal sparing pattern", "Circumferential strain >-15%", "Longitudinal strain <10% with basal predominance"], "answer": "B", "answer_index": 1, "explanation": "Relative apical sparing ratio (average apical strain / average basal strain) >1.5 is 93% specific for cardiac amyloidosis, reflecting base-to-apex gradient of amyloid deposition. This pattern is not seen in hypertensive heart disease where strain reduction is homogeneous.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is medically accurate and logically sound. The clinical vignette describes a patient with wild-type transthyretin amyloidosis (ATTRwt) and asks for the speckle-tracking echocardiography finding that best distinguishes this condition from hypertensive heart disease (HHD). Both conditions present with left ventricular hypertrophy (LVH) and preserved or reduced ejection fraction. However, the hallmark strain imaging finding in cardiac amyloidosis is 'apical sparing' (reduced longitudinal strain at the base, preserved at the apex), often visualized as a 'cherry-on-top' bullseye plot. Option B (Relative apical sparing ratio >1.5) correctly identifies the quantitative metric for this specific pattern. Option A (reduced GLS) is seen in both conditions, though often more severe in amyloid, making it less specific than the pattern itself. Option C describes the opposite pattern. Option D is not the primary discriminator. The key is supported by major guidelines and literature (e.g., Phelan et al.).\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is medically accurate and logically sound. The clinical vignette describes a patient with wild-type transthyretin amyloidosis (ATTRwt) and asks for the speckle-tracking echocardiography finding that best distinguishes this condition from hypertensive heart disease (HHD). Both conditions present with left ventricular hypertrophy (LVH) and preserved or reduced ejection fraction. However, the hallmark strain imaging finding in cardiac amyloidosis is 'apical sparing' (reduced longitudinal strain at the base, preserved at the apex), often visualized as a 'cherry-on-top' bullseye plot. Option B (Relative apical sparing ratio >1.5) correctly identifies the quantitative metric for this specific pattern. Option A (reduced GLS) is seen in both conditions, though often more severe in amyloid, making it less specific than the pattern itself. Option C describes the opposite pattern. Option D is not the primary discriminator. The key is supported by major guidelines and literature (e.g., Phelan et al.).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-009", "question": "A 45-year-old woman with severe verapamil overdose (ingestion 4 hours ago) presents with hypotension (SBP 70mmHg) and hyperglycemia (420mg/dL). You initiate high-dose insulin euglycemia therapy (HIET). What is the target serum glucose range during the first 24 hours?", "options": ["80-110 mg/dL (tight glycemic control)", "110-180 mg/dL (moderate control)", "180-250 mg/dL (permissive hyperglycemia)", "250-350 mg/dL (severe hyperglycemia acceptable)", "No specific target; follow institutional protocol"], "answer": "B", "answer_index": 1, "explanation": "HIET requires maintaining glucose 110-180 mg/dL to prevent hypoglycemia during high-dose insulin infusion (0.5-1 unit/kg/hr) while allowing insulin's inotropic effects. Tighter targets risk hypoglycemia; higher targets may impair insulin's metabolic benefits.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The vignette describes a patient with severe calcium channel blocker toxicity requiring High-dose Insulin Euglycemia Therapy (HIET). The question asks for the target glucose range. While the patient is currently hyperglycemic (a common effect of CCB toxicity due to inhibition of insulin release), the massive doses of insulin used in HIET (0.5–10 U/kg/hr) necessitate careful monitoring to maintain 'euglycemia' and prevent iatrogenic hypoglycemia. The keyed answer (B: 110–180 mg/dL) aligns with standard critical care glucose management guidelines (e.g., NICE-SUGAR study results) which recommend avoiding tight control (80–110 mg/dL) due to hypoglycemia risk, while also avoiding severe hyperglycemia. Toxicology resources for HIET typically recommend maintaining glucose between 100–200 mg/dL. Option B is the most consistent with established safety standards. Options A, C, and D represent outdated or non-standard targets. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The vignette describes a patient with severe calcium channel blocker toxicity requiring High-dose Insulin Euglycemia Therapy (HIET). The question asks for the target glucose range. While the patient is currently hyperglycemic (a common effect of CCB toxicity due to inhibition of insulin release), the massive doses of insulin used in HIET (0.5–10 U/kg/hr) necessitate careful monitoring to maintain 'euglycemia' and prevent iatrogenic hypoglycemia. The keyed answer (B: 110–180 mg/dL) aligns with standard critical care glucose management guidelines (e.g., NICE-SUGAR study results) which recommend avoiding tight control (80–110 mg/dL) due to hypoglycemia risk, while also avoiding severe hyperglycemia. Toxicology resources for HIET typically recommend maintaining glucose between 100–200 mg/dL. Option B is the most consistent with established safety standards. Options A, C, and D represent outdated or non-standard targets. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-010", "question": "A 35-year-old man develops DRESS syndrome 3 weeks after starting phenytoin. He has fever, eosinophilia, atypical lymphocytosis, and transaminitis (AST 450 U/L). HHV-6 PCR becomes positive at day 16 of illness. What is the clinical significance of this virologic finding?", "options": ["Confirms phenytoin as the causative drug", "Indicates need for ganciclovir antiviral therapy", "Predicts higher risk of disease flare and organ damage", "Represents asymptomatic viral reactivation without prognostic value", "Suggests alternative diagnosis of acute HHV-6 infection"], "answer": "C", "answer_index": 2, "explanation": "HHV-6 reactivation at weeks 2-3 in DRESS is pathogenically linked to disease severity, predicting higher risk of relapse, end-organ damage, and prolonged course. It indicates need for more aggressive immunosuppression, not antiviral therapy, as the virus is a marker of immune dysregulation.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question accurately tests the pathophysiology and prognostic implications of DRESS syndrome. DRESS is frequently associated with the reactivation of human herpesviruses, particularly HHV-6, which typically occurs 2–4 weeks after symptom onset. Option C is the correct best answer, as medical literature consistently links HHV-6 reactivation in DRESS to a more severe clinical course, higher rates of visceral involvement, and increased risk of relapses or flares. Option B is incorrect because the standard of care for DRESS involves withdrawal of the offending drug and immunosuppression (corticosteroids); antiviral therapy is not routinely indicated for the viremia associated with DRESS unless specific severe complications (e.g., encephalitis) arise, which are not described here. Option E is incorrect because HHV-6 reactivation is a component of DRESS pathophysiology, not an alternative diagnosis. Option A is incorrect as the drug history identifies the cause, not the virus. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question accurately tests the pathophysiology and prognostic implications of DRESS syndrome. DRESS is frequently associated with the reactivation of human herpesviruses, particularly HHV-6, which typically occurs 2–4 weeks after symptom onset. Option C is the correct best answer, as medical literature consistently links HHV-6 reactivation in DRESS to a more severe clinical course, higher rates of visceral involvement, and increased risk of relapses or flares. Option B is incorrect because the standard of care for DRESS involves withdrawal of the offending drug and immunosuppression (corticosteroids); antiviral therapy is not routinely indicated for the viremia associated with DRESS unless specific severe complications (e.g., encephalitis) arise, which are not described here. Option E is incorrect because HHV-6 reactivation is a component of DRESS pathophysiology, not an alternative diagnosis. Option A is incorrect as the drug history identifies the cause, not the virus. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]